Sara Tolaney· @stolaney1 · X·· 2 天前评分90
正文 · 机器翻译
PANKU-Breast01
HR+ MBC，既往接受过 cdk 4/6i，既往接受过1-2线化疗
Iza-bren vs TPC
约70%接受过1线化疗
PFS 8.2个月 vs 4.0个月，HR 0.41，p<0.0001
ORR 40.5% vs 20.2%
DOR 6.9个月 vs 4.2个月
OS数据尚不成熟
最常见毒性：血液学毒性，无需常规使用GCSF
@OncoAlert #ESMO26
451 浏览 · 8 赞 · 8 转发 · 0 回复
会议摘要
LBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.org来源：Sara Tolaney · x.com